R T O'Donnell|B R Andersen - JoVE Visualize

Showing results (81-90 of 103) with videos related to

Pageof 11

Sort By:

Cellular Immunology|February 12, 1999

Mycobacterium avium complex activates nuclear factor kappaB via induction of inflammatory cytokinesM Ghassemi, B R Andersen, K A Roebuck, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2001

Metabolite production in patients with lymphoma after radiometal-labeled antibody administrationG L DeNardo, S J DeNardo, D L Kukis, et al.

European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 21, 2023

Risk factors for and consequences of difficult fetal extraction in emergency caesarean section. A retrospective registry-based cohort studyI L A Ammitzbøll, B R Andersen, K H W Lange, et al.

Cancer Biotherapy & Radiopharmaceuticals|June 14, 2000

Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenograftsR T O'Donnell, S J DeNardo, L A Miers, et al.

The Prostate|October 6, 1998

L6 monoclonal antibody binds prostate cancerR T O'Donnell, S J DeNardo, X B Shi, et al.

Journal of the International Neuropsychological Society : JINS|July 10, 1998

Information processing and antiretroviral therapy in HIV-1 infectionE M Martin, D L Pitrak, K J Pursell, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2000

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphomaG L DeNardo, R T O'Donnell, S Shen, et al.

Clinical Lymphoma|November 15, 2001

Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphomaG L DeNardo, S J DeNardo, R T O'Donnell, et al.

Cancer|December 24, 1997

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinomaS J DeNardo, L A Kroger, K R Lamborn, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancerSally J DeNardo, Carol M Richman, Huguette Albrecht, et al.

Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:

Pageof 11

Cellular Immunology|February 12, 1999

Mycobacterium avium complex activates nuclear factor kappaB via induction of inflammatory cytokinesM Ghassemi, B R Andersen, K A Roebuck, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2001

Metabolite production in patients with lymphoma after radiometal-labeled antibody administrationG L DeNardo, S J DeNardo, D L Kukis, et al.

European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 21, 2023

Risk factors for and consequences of difficult fetal extraction in emergency caesarean section. A retrospective registry-based cohort studyI L A Ammitzbøll, B R Andersen, K H W Lange, et al.

Cancer Biotherapy & Radiopharmaceuticals|June 14, 2000

Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenograftsR T O'Donnell, S J DeNardo, L A Miers, et al.

The Prostate|October 6, 1998

L6 monoclonal antibody binds prostate cancerR T O'Donnell, S J DeNardo, X B Shi, et al.

Journal of the International Neuropsychological Society : JINS|July 10, 1998

Information processing and antiretroviral therapy in HIV-1 infectionE M Martin, D L Pitrak, K J Pursell, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2000

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphomaG L DeNardo, R T O'Donnell, S Shen, et al.

Clinical Lymphoma|November 15, 2001

Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphomaG L DeNardo, S J DeNardo, R T O'Donnell, et al.

Cancer|December 24, 1997

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinomaS J DeNardo, L A Kroger, K R Lamborn, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancerSally J DeNardo, Carol M Richman, Huguette Albrecht, et al.

Pageof 11